Browse News
Filter News
Found 73 articles
-
NeuroSense Therapeutics Reports Positive Final Results from Alzheimer's Biomarker Study
1/19/2023
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced final results from a biomarker study conducted to evaluate the potential of NeuroSense's combination platform therapy for the treatment of Alzheimer's disease (AD).
-
NeuroSense Announces Third Quarter 2022 Financial Results and Provides Business Update
12/1/2022
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced its financial results for the quarter ended September 30, 2022 and provided a business update.
-
NeuroSense Receives Regulatory Approval to Commence Patient Enrollment in Italy for its Phase 2b Trial in ALS
11/16/2022
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced it has received approval from the Italian Medicines Agency (AIFA) to commence patient enrollment in Italy for PARADIGM, the Company's Phase 2b clinical trial of its lead drug candidate PrimeC in the treatment of amyotrophic lateral sclerosis (ALS).
-
NeuroSense Receives FDA Clearance of IND for its ALS Phase 2b Study
11/15/2022
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) to enroll patients in the U.S. for its Phase 2b PARADIGM study for its lead drug candidate PrimeC in the treatment of amyotrophic lateral sclerosis (ALS).
-
NeuroSense Therapeutics to Present at Upcoming Leading Neuroscience Conferences
10/27/2022
NeuroSense Therapeutics Ltd. today announced its participation in three upcoming conferences.
-
NeuroSense Therapeutics Provides CEO's Q3 Update and Nasdaq Opening Bell Ceremony Remarks Video
10/18/2022
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today provided a Q3 update and released the video of Founder and CEO Alon Ben-Noon's remarks at the Nasdaq Opening Bell Ceremony on October 13, 2022.
-
NeuroSense Therapeutics to Ring Nasdaq Opening Bell and Host The ALS Combination Therapy Summit on October 13, 2022 in New York City
10/12/2022
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced its management team will participate in an Opening Bell Ceremony at the Nasdaq Stock Market on Thursday, October 13, 2022.
-
NeuroSense CEO to be Panelist at Cantor Neurology and Psychiatry Conference
9/29/2022
NeuroSense Therapeutics Ltd. today announced it will participate in Cantor Fitzgerald's Cantor Neurology and Psychiatry Conference scheduled to take place October 6-7, 2022 in San Francisco.
-
A new formulation of NeuroSense’s amyotrophic lateral sclerosis therapeutic PrimeC could pave the way for an expansion of its ongoing Phase IIb PARADIGM study into the United States.
-
NeuroSense Announces Positive PrimeC Pharmacokinetic Study Results & Anticipates Phase IIb ALS Enrollment to Expand into the US
9/28/2022
NeuroSense Therapeutics Ltd. today announced results from its multi-dose PK study (NCT05436678) of its lead drug candidate PrimeC for the treatment of amyotrophic lateral sclerosis (ALS).
-
Alaunos Therapeutics, Satsuma Pharmaceuticals, NeuroSense, Emyria and more reported updates in solid tumors, migraine, ALS and MDMA drug discovery.
-
NeuroSense Therapeutics to Present at Upcoming U.S. and European ALS Conferences
9/21/2022
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced scientific presentations at two upcoming conferences.
-
NeuroSense Announces Positive PrimeC Toxicology Data Supportive of Current Phase IIb PARADIGM ALS Clinical Trial
9/20/2022
NeuroSense Therapeutics Ltd. today announced positive results from its Good Laboratory Practices (GLP) toxicology study designed to evaluate the toxicological profile and toxicokinetics of the combination of celecoxib and ciprofloxacin, the components of PrimeC, the Company's lead combination drug candidate for the treatment of amyotrophic lateral sclerosis (ALS).
-
NeuroSense Announces Peer-Reviewed Publication of PrimeC Phase IIa ALS Study in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
9/19/2022
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), today announced the peer-reviewed publication of Phase IIa clinical data in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration in a paper titled, "Combination of ciprofloxacin/celecoxib as a novel therapeutic strategy for ALS" authored by NeuroSense's Head of Scientific Program, Dr. Shiran Zimri, and Head of ALS Program, Avital Pushett, along with leading amyotrophic lateral sclerosis (ALS) researchers.
-
There are several approaches on the horizon in ALS, a space that is gaining momentum. BioSpace spoke with GeNeuro, NeuroSense and the Tisch MS Research Center about their progress.
-
NeuroSense Announces Second Quarter 2022 Financial Results and Provides Business Update
8/31/2022
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today published its financial results for the quarter ended June 30, 2022 and provided a business update.
-
Adial Pharmaceuticals Names Cary Claiborne as Chief Executive Officer
8/22/2022
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced the appointment of Cary J. Claiborne as President and Chief Executive Officer.
-
CytRx Welcomes Cary J. Claiborne to the CytRx Board of Directors
8/9/2022
CytRx Corporation welcomes Mr. Cary J. Claiborne to the CytRx Board of Directors (the “Board").
-
NeuroSense Joins EverythingALS Open Innovation Consortium; Set to Enroll US and EU Patients in Phase IIb Study
8/2/2022
EverythingALS, today announced NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, as a new collaborator in the effort to identify treatments and a cure for ALS.
-
NeuroSense Therapeutics and NeuraLight Collaborate to Detect ALS Oculometric Biomarkers Using AI and ML
7/28/2022
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), and NeuraLight, a company developing objective and sensitive biomarkers for neurological disorders, today announced a collaboration to advance the science of digital biomarkers in the detection and monitoring of neurological diseases including amyotrophic lateral sclerosis (ALS).